** U.S-listed shares of drug developer NewAmsterdam Pharma NAMS.O fall as much as 5.8%; last down 4.7% at $24.95
** NAMS late Tuesday announced commencement of a $300 mln public offering of shares and pre-funded warrants
** Offering commenced after NAMS terminated up to $150 mln "at-the-market" stock sale agreement with TD Cowen
** Jefferies, Goldman Sachs, Leerink Partners, TD Cowen, Guggenheim Securities and William Blair are the joint book-running managers for the offering
** Stock also rose 41.4% on Tuesday after NAMS reported data from a late-stage study that showed its experimental drug significantly reduced levels of low-density lipoprotein cholesterol
** NAMS has 92.4 mln outstanding shares and a $2.42 bln market capitalization as of last close - LSEG data
** As of last close, NAMS shares had more than doubled YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。